Crispr Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Oppenheimer issued their Q1 2020 earnings per share (EPS) estimates for Crispr Therapeutics in a report released on Tuesday, November 12th, according to Zacks Investment Research. Oppenheimer analyst S. Tuerkcan anticipates that the company will earn ($0.87) per share for the quarter. Oppenheimer currently has a “Outperform” rating and a $80.00 target price on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ FY2021 earnings at ($4.29) EPS, FY2022 earnings at ($4.70) EPS and FY2023 earnings at ($1.07) EPS.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The firm had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million.
Several other research analysts have also issued reports on the stock. ValuEngine upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Chardan Capital restated a “buy” rating and set a $72.50 price target on shares of Crispr Therapeutics in a report on Monday, November 18th. William Blair upgraded shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a research note on Tuesday, November 19th. Finally, TheStreet upgraded shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $69.54.
Crispr Therapeutics stock opened at $71.65 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $74.00. The firm has a 50 day moving average price of $49.98 and a two-hundred day moving average price of $46.23. The firm has a market cap of $3.76 billion, a price-to-earnings ratio of -20.83 and a beta of 3.15.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BSW Wealth Partners acquired a new stake in Crispr Therapeutics in the 2nd quarter valued at $39,000. Balyasny Asset Management LLC purchased a new position in Crispr Therapeutics during the 2nd quarter worth $5,165,000. BNP Paribas Arbitrage SA purchased a new position in Crispr Therapeutics during the 2nd quarter worth $41,000. Bank of New York Mellon Corp boosted its holdings in Crispr Therapeutics by 116.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock worth $1,559,000 after acquiring an additional 17,810 shares during the last quarter. Finally, ARK Investment Management LLC boosted its holdings in Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after acquiring an additional 701,332 shares during the last quarter. 49.81% of the stock is owned by institutional investors and hedge funds.
In related news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock valued at $3,620,760 in the last quarter. 21.40% of the stock is currently owned by company insiders.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: Profit Margin
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.